



LATE-NC staging in routine neuropathologic diagnosis: an update

Peter T. Nelson¹ · Edward B. Lee² · Matthew D. Cykowski³ · Irina Alafuzoff⁴ · Konstantinos Arfanakis^{5,6} · Johannes Attems⁷ · Carol Brayne⁸ · Maria M. Corrada⁹ · Brittany N. Dugger¹⁰ · Margaret E. Flanagan¹¹ · Bernardino Ghetti¹² · Lea T. Grinberg¹³ · Murray Grossman² · Michel J. Grothe¹⁴ · Glenda M. Halliday¹⁵ · Masato Hasegawa¹⁶ · Suvi R. K. Hokkanen⁸ · Sally Hunter⁸ · Kurt Jellinger¹⁷ · Claudia H. Kawas⁹ · C. Dirk Keene¹⁸ · Naomi Kouri¹⁹ · Gabor G. Kovacs^{20,21,22,23} · James B. Leverenz²⁴ · Caitlin S. Latimer¹⁸ · Ian R. Mackenzie²⁵ · Qinwen Mao²⁶ · Kirsty E. McAleese⁷ · Richard Merrick⁸ · Thomas J. Montine²⁷ · Melissa E. Murray¹⁹ · Liisa Myllykangas²⁸ · Sukriti Nag⁵ · Janna H. Neltner¹ · Kathy L. Newell¹² · Robert A. Rissman²⁹ · Yuko Saito³⁰ · S. Ahmad Sajjadi⁹ · Katherine E. Schwetye³¹ · Andrew F. Teich³² · Dietmar R. Thal^{33,34} · Sandra O. Tomé³³ · Juan C. Troncoso³⁵ · Shih-Hsiu J. Wang³⁶ · Charles L. White III³⁷ · Thomas Wisniewski³⁸ · Hyun-Sik Yang³⁹ · Julie A. Schneider⁵ · Dennis W. Dickson¹⁹ · Manuela Neumann⁴⁰

Received: 18 October 2022 / Revised: 21 November 2022 / Accepted: 22 November 2022
© The Author(s) 2022

Abstract

An international consensus report in 2019 recommended a classification system for limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (LATE-NC). The suggested neuropathologic staging system and nomenclature have proven useful for autopsy practice and dementia research. However, some issues remain unresolved, such as cases with unusual features that do not fit with current diagnostic categories. The goal of this report is to update the neuropathologic criteria for the diagnosis and staging of LATE-NC, based primarily on published data. We provide practical suggestions about how to integrate available genetic information and comorbid pathologies [e.g., Alzheimer's disease neuropathologic changes (ADNC) and Lewy body disease]. We also describe recent research findings that have enabled more precise guidance on how to differentiate LATE-NC from other subtypes of TDP-43 pathology [e.g., frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)], and how to render diagnoses in unusual situations in which TDP-43 pathology does not follow the staging scheme proposed in 2019. Specific recommendations are also made on when not to apply this diagnostic term based on current knowledge. Neuroanatomical regions of interest in LATE-NC are described in detail and the implications for TDP-43 immunohistochemical results are specified more precisely. We also highlight questions that remain unresolved and areas needing additional study. In summary, the current work lays out a number of recommendations to improve the precision of LATE-NC staging based on published reports and diagnostic experience.

Keywords Dementia · Processes · NCI · TDP-43 · FTD · Stages · Hippocampal sclerosis · Neuroanatomy · Aging

Abbreviations

ADNC	Alzheimer's disease neuropathologic change
ALS	Amyotrophic lateral sclerosis
CTE	Chronic traumatic encephalopathy
FTD	Frontotemporal dementia
FTLD	Frontotemporal lobar degeneration
HS	Hippocampal sclerosis
LATE-NC	Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change

NCI	Neuronal cytoplasmic inclusions
TDP-43	Transactive response (TAR) DNA-binding protein of 43 kDa

Introduction

Transactive response DNA-binding protein of 43 kDa (TDP-43) pathology is prevalent in aging brains and is often associated with cognitive impairment or dementia [114]. Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117,

✉ Peter T. Nelson
pnels2@email.uky.edu

Extended author information available on the last page of the article

Brain sampling for routine autopsy diagnosis of LATE-NC

1. Amygdala; 2. Hippocampus; 3. Middle frontal gyrus




Fig. 1 Anatomical regions of interest for tissue sampling and typical findings in routine autopsy diagnosis of LATE-NC. At autopsy, tissue portions for sampling include amygdala, mid-level hippocampus, and middle frontal gyrus. The levels of sections are shown in the cartoon form (upper left) with gross photographs of hemi-brains cut in the coronal plane (Panel a). Note that the amygdala is preferably sampled for TDP-43 immunohistochemical staining at the level of the uncus (pink arrowhead, Sect. 1), the hippocampus at the level of the lateral geniculate nucleus (yellow arrowhead, Sect. 2), and the middle frontal gyrus (Sect. 3) is sampled rather than other portions of frontal cortex. Panels b and c are representations of the amygdala region and hippocampal region, showing both the local anatomy and a cursory depiction of the subtypes of TDP-43 pathology that are generally found in those regions with corresponding colored circles in panels d-h. Panel d shows a neuronal TDP-43 + inclusion reminiscent of a neurofibrillary tangle. Panel e depicts a different TDP-43 pathologic appearance with a granular NCI (arrow with red outline), neuronal intranuclear inclusion (arrow with blue outline), and TDP-43 + fibrillary material in the background. This pattern is reminiscent of FTL-D-TDP type A. TDP-43 pathology can also be present around vascular components such as capillaries (termed Lin Bodies after Ref. [87]) or in unknown histologic compartments as shown in Panel f. In some regions, the predominant TDP-43 + pathology is fine non-tapering neurite-like processes (Panel g). A different type of TDP-43-immunoreactive cell processes can be seen in the sub-pial region, often near corpora amylacea (arrow in Panel h). Scale bars = 50 microns (d); 30 microns (e); 30 microns (f); 100 microns (g); and, 30 microns (h). Abbreviations: Amyg: amygdala proper; dg: dentate granule layer of hippocampus; ErC: entorhinal cortex; LGN: lateral geniculate nucleus; LV: lateral ventricle; NCI: TDP-43 immunoreactive neuronal cytoplasmic inclusions; NFT: neurofibrillary tangles; TeRC: transentorhinal cortex; Unc: uncus

125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently. In 2019, a multidisciplinary consensus group suggested terminology for age-related TDP-43 pathologic changes associated with cognitive impairment. The disease was designated “limbic-predominant age-related TDP-43 encephalopathy” (LATE) [114], and guidelines were suggested for post-mortem evaluation and staging of LATE neuropathologic changes (LATE-NC). This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153]. However, diagnostic ambiguities and criticisms of the staging scheme have emerged [22, 61, 115].

At least four shortcomings have been identified in the 2019 LATE-NC guidelines: (1) anatomic regions for sampling were recommended, but the implications of TDP-43 immunopositivity in subregions were not precisely defined; (2) it was not clear how additional information on genetic findings and other pathologies should be incorporated into reports of LATE-NC; (3) there was minimal guidance on how to separate LATE-NC from other TDP-43 proteinopathies; and (4) some cases with TDP-43 pathology in aging could not be readily classified into LATE-NC stages.

The aims of the present paper are to remedy these shortcomings, to provide data to clarify the proper use of the LATE-NC staging system, and to indicate where the diagnosis of LATE-NC may not be appropriate. The overarching

goal is to provide additional precision about LATE-NC diagnosis for neuropathologists. These goals are important, since brain autopsy remains the gold-standard for neurodegenerative disease diagnoses. New recommendations and clarifications are proposed for the LATE-NC staging system, guided by published data, findings reported at the LATE 2022 Conference [1] and diagnostic experience.

LATE-NC: recommendations for anatomic sampling and staining

Regarding brain tissue collected at autopsy to assess LATE-NC, this update does not propose additional sampling relative to the 2019 consensus recommendations [114]. However, there is a need to clarify the implications of the immunostaining results within specific regions of interest. Three anatomical regions are recommended for sampling, with the following suggestions (Fig. 1):

- (1) **Amygdala region:** this refers to the amygdala and surrounding structures at the level of the uncus, including adjacent entorhinal [Brodmann area (BA) 28], transentorhinal (BA35), anterior temporal (BA36) cortices and anterior parts of the hippocampus and the subiculum/presubiculum, sub-pial, subependymal regions, and white matter. The pathology is scored as positive in this region if aberrant TDP-43 immunoreactivity is seen anywhere on the section that contains amygdala and uncus (not just within amygdala proper).
- (2) **Hippocampus region:** this refers to the hippocampus and associated medial temporal cortical structures at the level of the lateral geniculate nucleus. Areas of interest may include fornix, sub-pial region, periventricular region, dentate granule cells, mid-level temporal cortex (BA36), and white matter. This region is considered to be positive if any part of the section has TDP-43 immunoreactive pathology.
- (3) **Middle frontal gyrus** (corresponding roughly to BA46). TDP-43 immunoreactive cytoplasmic inclusions in any part of this section is considered to be positive.

Supplemental File 1 (online resource) provides additional detail on the specific anatomical regions and subregions of interest, as pertains to LATE-NC staging.

The LATE-NC staging guidelines suggested that TDP-43 immunohistochemistry should be performed as part of the neuropathologic evaluation of all older individuals' brains [114], but there was no specific recommendation on the staining methods used. The antibody used for pathologic diagnosis and associated protocols may affect the ability to detect TDP-43 inclusions [40, 53, 79]. Phosphorylation-specific antibodies, with those against pS409/410 being the

most commonly used [44, 120], robustly label pathologic TDP-43 inclusions and do not stain normal (nonphosphorylated) nuclear TDP-43 protein, thereby facilitating identification of aggregates [35] but precluding the visualization of the loss of normal nuclear TDP-43 protein in inclusion bearing cells and nuclear staining as internal positive control. Antibodies that are phosphorylation independent allow for labeling of inclusions (albeit slightly less sensitively), while also enabling assessment of normal nuclear TDP-43 protein [40, 53, 79]. In an informal survey of U.S. Alzheimer's Disease Research Centers, approximately 2/3rd of the neuropathologists depended on antibodies against the phosphorylated Ser409/Ser410 TDP-43 epitope [71]. More standardization may be achievable in the future, but there is still not a current consensus on a prescribed set of reagents for TDP-43 detection.

LATE-NC: recommendations for pathological staging

LATE-NC staging, like other neurodegenerative disease staging systems [12, 18–20, 140], is based on anatomical regions affected by the neuropathologic changes. Following prior studies which incorporated analyses of TDP-43 immunohistochemical data from more anatomical regions [63, 64, 105, 107, 146, 162], the 2019 consensus guidelines for LATE-NC suggested that TDP-43 pathology progressed in a stereotypical pattern: LATE-NC Stage 1 corresponds to TDP-43 pathology in the amygdala, Stage 2 corresponds to TDP-43 pathology in the amygdala and hippocampus, and Stage 3 corresponds to TDP-43 pathology in the amygdala, hippocampus, and middle frontal gyrus [114]. If other neocortical regions (orbitofrontal cortex, or temporal neocortex) are stained and show neuronal cytoplasmic inclusions (NCIs), but NCIs are not seen in the middle frontal gyrus, this would not represent LATE-NC Stage 3. Some such LATE-NC Stage 2 cases would be expected, because orbitofrontal cortex and temporal neocortex (as well as some other regions) are affected earlier than middle frontal gyrus in the anatomical progression of LATE-NC [64, 105]. While most cases can be readily assigned to a given LATE-NC stage using those criteria, recent reports have described cases that depart from the staging scheme for one or more reasons [21, 29, 41, 62, 143, 147]. Below are described strategies to address various diagnostic challenges in a data-driven and standardized manner.

Brains with TDP-43 + NCI detected in the hippocampal region, but not in the amygdala region

In recently published studies from five separate autopsy series [29, 41, 80, 109, 143], a small subset of cases from

each cohort was reported with TDP-43 pathology in the hippocampal formation, but not in the amygdala. This pattern is not accounted for in the original LATE-NC staging guidelines [114]. LATE-NC cases with hippocampal TDP-43 + NCIs, but none in amygdala region, are unusual (<2% of LATE-NC cases), and the TDP-43 pathology usually involves the anterior hippocampus. These cases lacking detectable amygdala TDP-43 pathology may be due in part to sampling issues, and the clinical implications are unclear. More work is required to confirm that hippocampus-only TDP-43 pathology is appropriately diagnosed as LATE-NC. At present, because such cases have a low burden of TDP-43 pathology overall, and we do not know of an example of an individual with cognitive impairment lacking other pathologies, we recommend that this pattern of TDP-43 pathology be designated LATE-NC Stage 1.

To account for the varied pathologic patterns in LATE-NC Stage 1 cases, a system for differentiating subtypes of LATE-NC Stage 1 cases is now recommended. This classification may be most suitable for academic research centers, and should be considered optional for diagnosticians. In this system, a “conventional” case with TDP-43 immunoreactive NCI(s) in amygdala but not hippocampus would be diagnosed as LATE-NC Stage 1a, whereas an unusual case with NCI(s) in hippocampus but none detected in the amygdala region would be diagnosed as LATE-NC Stage 1b (Table 1).

Brains with TDP-43 + cell processes, but no TDP-43 + neuronal cytoplasmic inclusions (NCI)

In LATE-NC, TDP-43 proteinopathy is often detected in cellular compartments outside of the neuronal cell body [11, 29, 39, 116]. A recent study focusing on cases with minimal or incipient LATE-NC described cases without NCI, but with short, non-branching TDP-43 immunoreactive structures that frequently localized around corpora amylacea, and/or in aging-related tau astroglial pathology (ARTAG) pathology [29, 37, 110, 128]. Because of the apparent astroglial derivation of some TDP-43 pathology outside of neuronal cell bodies, we use the term “processes”, as opposed to “neurites”, for these common TDP-43-immunoreactive structures. TDP-43-positive processes were detected in the sub-pial zone overlying the corticomедial region of the amygdala and/or in the periventricular white matter subjacent to amygdala. This pattern was common—aberrant TDP-43 was found only in cellular processes in approximately one-third of LATE-NC cases [29]. Another recent study confirmed that there are cases with TDP-43 + processes but lacking TDP-43 + NCIs [80].

We propose that cases with only TDP-43-positive processes, and no NCI in the amygdala and hippocampus regions, should be diagnosed as LATE-NC Stage 1. It is emphasized that LATE-NC Stage 2 requires at least

Table 1 Specific pathological combinations and corresponding recommendations for LATE-NC staging

	Amygdala region*		Hippocampal region*		Middle frontal gyrus	LATE-NC Stage
	NCI(s)	Process(es)	NCI(s)	Process(es)	NCI(s)	
TDP-43 pathology: present (+) or absent (-)	+	Either + or -	-	Either + or -	-	1 (optional 1a)
	-	Either + or -	+	Either + or -	-	1 (optional 1b)
	-	+	-	Either + or -	-	1 (optional 1c)
	-	Either + or -	-	+	-	1 (optional 1c)
	+	Either + or -	+	Either + or -	-	2
	+	Either + or -	+	Either + or -	+	3**

*Amygdala region and hippocampal region refer to anatomical areas on the same slide

**See recommendations to distinguish LATE-NC Stage 3 from FTLD-TDP and ALS

a single NCI to be present in each of both the amygdala and hippocampal regions. In the context of the optional LATE-NC Stage 1 subtyping system as described above, any case with TDP-43 immunoreactive processes only (no NCI) would be LATE-NC Stage 1c, even if the TDP-43+ processes are in the hippocampus region. The various possible neuropathologic changes seen in LATE-NC Stage 1, and their relevant diagnoses, are shown in detail in Table 1. This staging scheme will help clarify diagnostic practice, but we also recognize that more work is required to understand the implications of aberrant TDP-43 protein in processes but not NCIs.

Brains with comorbid Alzheimer's disease neuropathologic changes (ADNC), Lewy bodies, and/or granulovacuolar degeneration

It has been recognized for over a decade that TDP-43 pathology is often comorbid with ADNC, Lewy body pathology, or both [8, 10, 46, 66, 67]. However, these pathologic features also are commonly seen—even when quite severe—in the absence of each other [51, 52, 88, 113, 147, 153, 154], so they are at least partly independent. Many studies have demonstrated that LATE-NC is associated with additive cognitive impairment for a given amount of other pathologic changes [4, 16, 17, 72, 103, 111, 127]. Therefore, we recommend that descriptions of the individual diseases (and their neuropathologic stages) be rendered as separate line diagnoses on autopsy reports. A potential pitfall for the assessment of LATE-NC is the fact that some phospho-TDP-43 antibodies also detect granulovacuolar degeneration (GVD) [51, 69, 76, 139, 151]—this staining is not considered to represent LATE-NC. For more data and discussion related to immunostaining of GVD, see Refs [51, 69, 76, 77, 141, 151].

Differentiating LATE-NC from other pathologies

Differentiating LATE-NC Stage 3 from FTLD-TDP

TDP-43 was initially identified as a protein that forms abnormal intracellular aggregates in the most common pathology associated with clinical frontotemporal dementia (FTD) syndromes, now termed frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) and in ALS [122]. The defining feature of FTLD-TDP is the presence of NCIs and dystrophic TDP-43 immunoreactive processes in affected frontotemporal cortices [23, 93, 94, 122]. Differences in the morphologic features, abundance, and laminar distribution of TDP-43 pathology in the cerebral neocortex allow for recognition of at least five subtypes of FTLD-TDP, each with relatively specific clinical and genetic correlations and increasingly recognized molecular differences in the nature of the TDP-43 aggregates [84, 90, 92, 119, 121, 124]. In addition, each FTLD-TDP subtype has a fairly distinct pattern of limbic and subcortical involvement that is helpful in their classification [65, 91]. Nevertheless, potential pitfalls in the FTLD-TDP subtyping have been discussed due to the presence of mixed subtypes (usually FTLD-TDP types A + B), and overall low inter-rater agreement in separating FTLD-TDP types A and B [5, 9, 90].

Cases with TDP-43 pathology mostly restricted to the medial temporal lobes (LATE-NC Stages 1 or 2) do not fulfill criteria for FTLD-TDP and should be classified as LATE-NC. By contrast, boundaries between LATE-NC Stage 3 and FTLD-TDP are more challenging (~11% of LATE-NC cases in community-based cohorts were Stage 3 [113]). Ancillary measures, such as neuronal loss and gliosis, as well as superficial laminar spongiosis, involvement of further cortices and subcortical nuclei and white matter in FTLD-TDP, and the morphology of inclusions may help differentiate genuine FTLD-TDP from LATE-NC Stage 3. More work is needed

to delineate aspects of biological overlap and differences between LATE-NC and FTLD-TDP, particularly for FTLD-TDP in advanced old age [22].

Based on current knowledge, our recommendations are as follows:

- TDP-43 pathology in LATE-NC has histomorphologic features that may be similar to FTLD-TDP type A or less commonly type B [8, 114, 131, 149]. By contrast, all cases with FTLD-TDP types C, D, or E patterns [84] should be classified as FTLD-TDP and not LATE-NC.
- The severity of TDP-43 pathology in the middle frontal gyrus has been described as a useful indicator to differentiate LATE-NC Stage 3 from FTLD-TDP [131]. Specifically, more than 15 TDP-43 immunoreactive inclusions (NCIs and/or threads) per high power (40× objective) microscopic field in the middle frontal gyrus had a high sensitivity and specificity in differentiating FTLD-TDP from LATE-NC [131]. More than 15 TDP-43-immunoreactive pathological structures per 40× microscopic field in the middle frontal gyrus favor a diagnosis of FTLD-TDP or a descriptive diagnosis of the pathologies observed, rather than LATE-NC.
- In cases with substantial TDP-43 pathology in the middle frontal gyrus, it is recommended to expand regions sampled for TDP-43 pathology and to include regions more typically affected in FTLD-TDP, such as subcortical structures, including basal ganglia, medulla (hypoglossal nucleus), and spinal cord. TDP-43 pathology in these regions supports a diagnosis of FTLD-TDP or ALS.
- Cases with known pathogenetic mutations in FTLD-TDP-related genes (e.g., *GRN*, *C9orf72*, *VCP*, and others [99, 150]) should not be classified as LATE-NC. Notably, to identify *C9orf72* repeat expansion carriers, immunohistochemistry of cerebellum with antibodies against p62 or dipeptide repeat proteins can be used as surrogate markers. This method is recommended in standard histopathologic screening if genetic analyses are not available [89].
- Cases with comorbid FTLD-TDP and LATE-NC may exist, but there currently is no consensus about how to definitively diagnose such cases as distinct from FTLD-TDP alone.

Differentiating LATE-NC from amyotrophic lateral sclerosis (ALS)

Another important disease associated with TDP-43 proteinopathy is ALS. A four-tiered staging system of TDP-43 neuropathologic changes in ALS has been described by Brettschneider et al. [20] based on an autopsy cohort of ALS patients with average age at death of 63 years. TDP-43 pathology in the hippocampus region was designated stage 4 and was found in ~30% of cases. While, in this study, no

significant differences regarding age at disease onset, or age at death, were observed between different stages of TDP-43 pathology, a recent study found medial temporal lobe TDP-43 pathology in 8/8 older ALS cases (>75 years of age at death) [101], suggesting that in ALS, there may be pathology overlapping with LATE-NC. Yet, the TDP-43 neuropathologic changes in ALS differ from LATE-NC: motor neuron TDP-43 pathology has not been reported in LATE-NC, but is an early site of TDP-43 pathology in ALS [20], and is even seen in some FTLD-TDP cases without clinical ALS [32]. Until methods are available to distinguish TDP-43 pathology associated with LATE-NC from limbic pathology in ALS, we recommend avoiding the term LATE-NC in the context of sporadic and familial ALS.

Brains with unusual TDP-43 pathologies

Research continues to find expanding implications of aberrant TDP-43 protein in human diseases. TDP-43 pathology is now known to occur in more than 20 different conditions spanning neurodegenerative, developmental, trauma-related, myopathic, and even neoplastic disease categories [2, 13, 26, 27, 78, 83, 129, 133, 134, 157]. For example, TDP-43 pathology is often seen in corticobasal degeneration, Perry syndrome, Alexander disease, and the Parkinsonism–dementia complex diseases of Guam and Kii [43, 75, 148, 152, 156]. However, the morphology and anatomical patterns of the TDP-43 pathology in those conditions often differ from that in LATE-NC, so the diagnosis of LATE-NC should be avoided in these conditions. For persons with a clinical history of brain trauma—traumatic brain injury (TBI) and/or chronic traumatic encephalopathy (CTE)—TDP-43 pathologic changes may be seen, but not necessarily related to LATE-NC [3, 60, 96, 97, 126]. More work is required to develop a data-driven consensus of best practices for diagnosing brain trauma-related TDP-43 pathology.

Guidance in autopsy reports

Brain autopsy reports of individuals across the spectrum of dementias convey complex information reflecting the (often multifactorial) nature of the underlying diseases. That complexity, along with technical nomenclatures, can make it difficult, especially for patients' families and loved ones, to understand the implications of TDP-43 pathology. It may be helpful for practicing neuropathologists to provide interpretive summaries, but we emphasize that this should be a separate comment with a focus on interpretation of findings in nontechnical language [82].

What are the implications of LATE-NC staging results? Clinical–pathological studies demonstrated that LATE-NC is associated with cognitive impairment (often with amnesic

features), independent of other disease processes [17, 36, 42, 51, 58, 62, 68, 72, 88, 103, 104, 111, 130, 132, 135]. For example, in an attributable risk analysis based on all observed pathologic changes that may contribute to cognitive impairment in a large community cohort, LATE-NC accounted for more than 15% of identified amnesic dementia risk [16, 114]. Similar to other age-related neurodegenerative disease processes, it is not possible to confidently predict clinical implications of LATE-NC in a given individual, especially if there are multiple concurrent pathologies [24, 98, 108, 109, 112, 143, 146].

The following are possible text templates to complement the diagnostic findings in cases with LATE-NC:

- LATE-NC Stage 1 indicates the early/incipient stage of LATE-NC, analogous to early stages of other brain and systemic diseases where pathologies are present before outward clinical signs/symptoms (e.g., Braak NFT Stages I–II in Alzheimer’s disease Neuropathologic Changes). The presence of LATE-NC Stage 1 may be compatible with normal cognition or may have only a relatively small additive impact on cognitive function.
- LATE-NC Stage 2 indicates that TDP-43 neuronal cytoplasmic inclusions are detected more broadly in the brain. LATE-NC Stage 2 is usually associated with some impairment of memory or global cognition or both [114], with more cognitive impairment in cases with comorbid hippocampal sclerosis.
- LATE-NC Stage 3 indicates the most advanced stage of LATE-NC in terms of neuroanatomic distribution of TDP-43 pathologic burden in the brain. LATE-NC Stage 3 is usually associated with some degree of impairment of memory or global cognitive impairment [114], and with more cognitive impairment in cases with comorbid hippocampal sclerosis.

Future directions and knowledge gaps related to LATE-NC

Considering the major public health impact of LATE-NC, there are many aspects of this disorder that merit further research. Of greatest urgency is the need for a sensitive and specific method to diagnose LATE during life, ideally at early stages of disease, to enable focused recruitment into clinical trials. The involvement of aberrant TDP-43 in a wider range of brain areas, and the role(s) of astrocytes in pathogenesis could also be foci of further scholarship. Systematic neuropathological and clinicopathological studies will inform if the staging system needs modifications to include intermediate stages. Additional pressing research is needed to define and stratify risk factors and interactions with other diseases, including various neurodegenerative

and neurovascular disorders (see, for example, Refs [15, 37, 128]). Observations in more diverse communities are critical, since socioeconomic, cultural, and/or ancestral aspects may influence clinical–pathological correlation [55, 109, 123, 146]. (Some recent scholarship has evaluated LATE-NC in cohorts other than Whites [104, 109, 123, 146].)

It may be possible to discover molecular subtypes of LATE-NC using immunophenotyping, transcriptome profiling, and genotyping or other approaches, which has potential implications for prognosis and therapy. Indeed, there has already been significant progress along these lines [119, 143]. In particular, pathologic heterogeneity in LATE-NC has been demonstrated particularly in the early phases of LATE-NC, which occurs in different patterns and appears to originate at one of several different anatomic locations in the amygdala region [29, 62]. Certain parameters and features (e.g., comorbid Lewy body disease) have been associated with differing patterns of LATE-NC [29, 62]. A genetic risk factor for LATE-NC is *TMEM106B* [33]. Notably, the *TMEM106B* risk allele frequency was elevated in all identified LATE-NC patterns, and the different TDP-43 pathologic patterns observed in cases with mild pathology tended to converge in more severely affected brains [29]. We conclude that cases meeting criteria for LATE-NC encompass both heterogeneity and meaningful commonalities, but there currently is no agreement on means to differentiate LATE-NC subtypes.

Another area of uncertainty is the relation of LATE-NC to hippocampal sclerosis (HS). HS in the elderly is strongly associated with LATE-NC [7], with 75–90% of HS cases in aging being seen in cases with LATE-NC [34, 38, 47, 103, 106, 118]. The presence or absence of comorbid HS pathology does not affect LATE-NC staging. Further, HS is a diagnostic term that refers to distinctly different disease processes. For example, the diagnosis of HS is commonly applied in the context of persons with epilepsy, where the pathogenesis is very different (and lacks TDP-43 proteinopathy) in comparison to LATE-NC [118, 136, 142]. At autopsy, sensitive detection of HS requires bilateral sampling, because HS in LATE-NC is often unilateral [118, 161]. In hippocampi affected by severe HS, pyramidal cell dropout is extensive, and hippocampal atrophy can be extreme [6]; however, in some individuals with LATE-NC, cell loss is segmental (neuronal loss in some portions of the hippocampus and/or subiculum, but not others) [54]. These factors increase the likelihood of poor inter-rater agreement on the neuropathologic diagnosis of HS, and help explain the differing frequencies of HS reported in various autopsy series [34, 38, 73, 86, 88, 102, 118, 144, 159]. To fully standardize the pathologic diagnosis of HS, especially as it relates to differentiating LATE-NC + HS from other distinct disease processes (e.g., anoxic–ischemic episodes or seizures), will require

Table 2 LATE-NC Stages based on anatomic distribution of TDP-43 pathology: updates and clarifications for routine autopsy diagnoses

- Clarifications about anatomic regions of interest (ROI) for LATE-NC Stages 1 and 2:
 - "Amygdala region" (indicates any TDP-43 pathology in section that also includes amygdala at the level of the uncus)
 - "Hippocampus region" (indicates any TDP-43 pathology in section that also includes the mid-level hippocampus)
 - See Fig.1 and Suppl. 1, online resource, for more information about ROI
- Clarifications about early/incipient LATE-NC:
 - LATE-NC Stage 1 is relatively common in elderly persons with normal cognition and represents presumed incipient (often pre-clinical) disease
 - LATE-NC Stage 2 requires TDP-43+ neuronal cytoplasmic inclusions (NCIs) in both amygdala region and hippocampal region (but no TDP-43+ pathology in middle frontal gyrus)
 - LATE-NC Stages 1a-c diagnoses are optional:
 - LATE-NC Stage 1a: Amygdala region NCIs, no hippocampal region NCIs
 - LATE-NC Stage 1b: Hippocampal region NCIs, no amygdala region NCIs
 - LATE-NC Stage 1c: TDP-43 immunoreactive processes in the medial temporal lobe, but no NCIs identified
- Avoid the diagnosis of LATE-NC when there are unusual features identified, including:
 - The presence of FTLD-TDP subtype features other than FTLD-TDP types A or B
 - The presence of pathogenic mutations in FTLD-TDP and ALS disease genes and/or dipeptide repeat expansion (*C9orf72*)
 - High density of TDP-43 pathology in middle frontal gyrus
 - >15 TDP-43+ profiles per 40x microscopic field
 - Presence of TDP-43 pathology in neocortical region(s) but not amygdala or hippocampus regions
 - The presence of motor neuron TDP-43 pathology
- Diagnoses can be accompanied by separate notes in the autopsy report about likely clinical-pathologic correlation

additional work. Prior studies of HS-related histomorphology [45, 56, 160], and the recent work by Hokkanen et al. [47], provided methodologies to study HS pathologic features systematically.

In conclusion, despite challenges associated with a fast-moving research field, we found opportunities for recommendations to improve the precision of LATE-NC staging based on published reports and diagnostic experience. We emphasize that TDP-43 immunohistochemical assessment should be performed in all brain autopsies of older persons. The diagnosis of LATE-NC Stages requires sampling from three specific brain regions (Fig. 1, and Supplemental File 1, online resource). A specific rubric is presented in Table 1 and overall recommendations in Table 2. Recent literature indicates the scope of the challenge, even for this relatively simple pathologic staging system, as a wide variation of results was reported in the proportion of subjects with LATE-NC Stage 1 in a survey of community-based autopsy cohorts [113]. We hope that the present update will assist in efforts to increase standardization in the diagnosis of LATE-NC. As more observations are made across diverse autopsy cohorts, gathering detailed information on each case, including clinical, radiologic, laboratory,

neuropathology, and genetic data, may facilitate future refinements of the classification and staging of LATE-NC.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00401-022-02524-2>.

Acknowledgements We are profoundly grateful to the research participants, caregivers, clinicians, staff, and colleague scientists who contributed to this work.

Funding We acknowledge National Institutes of Health Grants P30 AG072958 (S.-H. J.W.), P30 AG072977 (M.E.F.), K08 AG065463 (M.E.F.), RF1 AG072080 (M.E.F.), K08 AG 065426 (C.S.L.), R01 AG038651 (E.L.A.), UF1 AG057707 (T.J.M and L.W.), R01 AG021055 (C.K. & M.C.), P30 AG066519 (UCI ADRC), R01 AG061111 (P.T.N.), R01 AG057187 (P.T.N.), P30 AG072946 (P.T.N.), RF1 NS118584 (M.D.C.), P01 AG066597 (E.B.L.), P30 AG072979 (E.B.L.), U19 AG062418 (E.B.L.), P30 AG072959 (Cleveland ADRC), R01 AG062706 (S.A.S.), R01 AG054449 (M.E.M.), R01 AG075802 (M.E.M.), P30 AG 066507 (J.T.), U19 AG033655 (J.T.), RF1 AG069052 (J.G.R.), P30 AG072972 (UC Davis ADRC), U19 AG069701 (M.E.M.), K24 AG053435 (L.T.G.), R01 AG067482 (J.A.S.), R01 AG064233 (J.A.S.), R01 AG022018 (J.A.S.), P30 AG010161/P30 AG072975 (J.A.S.), R01 AG064233 (K.A.), U01 AG061357 (B.N.D.), R01AG052132 (B.N.D.), R01 AG056519 (B.N.D.), R01 AG062517 (B.N.D.), a research grant from the California Department Of Public Health (19-10611) with partial funding from the

2019 California Budget Act (B.N.D.), K23 AG062750 (H.-S. Y.), U19 AG024904 (K.E.S.), R21 AG078538 (K.E.S.), P30 AG 010133 (B.G. and K.N.), P30 AG062677 (Mayo ADRC), P30 AG066512 (T.W.), UF1 NS125417 (R.C.P.), U01 AG006786 (MCSA), R01 AG034676 (REP), P30 AG066509 (UW ADRC), and U19 AG066567 (ACT Study). Academy of Finland (341007) (L.M.); State funding for university-level health research (TYH2020231, TYH2022316) (L.M.); Liv och Hälsa Foundation (L.M.); Rössy Foundation and the Edmond Safra Philanthropic Foundation (G.G.K.); NOMIS foundation and Alzheimer Forschung Initiative (#21004) (M.N.); and, (#13803) (D.R.T.); UK Medical Research Council (MRC) (MRC/G9901400, U.1052.00.0013, G0900582). Addenbrooke's Charitable Trust (S.H.), Addenbrooke's Charitable Trust Grant 900108 (S.H.), Paul G. Allen Foundation (S.H.), ARUK NSG (S.H.), Alzheimer's Society 554 (AS-PG-2019b-024) (S.H.), and the Nancy and Buster Alvord Endowment (C.D.K.). The Cambridge Brain Bank Laboratory is supported by the National Institute for Health Research, Cambridge Biomedical Research Centre. UK ARUK-PhD2014-19 (S.R.K.H.). Fonds Wetenschappelijk Onderzoek Vlaanderen (FWO: G0F8516N, G065721N) (D.R.T.); Stichting Alzheimer Onderzoek België (SAO-FRA: 2020/017) (D.R.T.); KU-Leuven Internal Funds (Belgium) (C14/17/107; C14/22/132; C3/20/057) (D.R.T.), (PDMT2/21/069) (S.O.T.); BrightFocus Foundation (A2022019F) (S.O.T.). "Miguel Servet" program (CP19/00031) (M.J.G.) and a research grant (PI20/00613) (M.J.G.) of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER). Alzheimer's Society (AS-JF-18-01; K.M.). Society for the Promotion of Research in Experimental Neurology, Vienna, Austria (K.J./Alzheimer's Research UK (ARUK) doctoral studentship (ARUK-PhD2017-34) (R.M.). AMED under Grant Number JP22wm0425019 (to Y.S.).

Data availability statement As this is a review/consensus paper, there are no data to be made available.

Declarations

Conflict of interest E.B.L., D.W.D., M.N., D.R.T., G.H., G.G.K., and P.T.N. are members of the Editorial Board of *Acta Neuropathologica* and J.A. is the Editor-in-Chief of *Acta Neuropathologica*, but none of the coauthors were involved in the Editorial handling of this article. D.R.T. received speaker honorary from Novartis Pharma AG (Switzerland) and Biogen (USA), travel reimbursement from GE-Healthcare (UK) and UCB (Belgium), and collaborated with Novartis Pharma AG (Switzerland), Probiobdrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- (2022) LATE 2022 Webinar, 11 February <https://www.nia.nih.gov/research/dn/late-2022>. Accessed 1 Nov 2022
- Agirre-Beitia G, Moreno-Estebanez A, Gonzalez-Pinto Gonzalez T, Melgar Jimenez B, Campos Rodriguez I, Cabral Martinez L et al (2020) FOSMN: a possible TDP-43 proteinopathy to consider in a patient with facial sensory symptoms. *Neurol Clin Pract* 10:e47–e50. <https://doi.org/10.1212/CPJ.0000000000000753>
- Agrawal S, Leurgans SE, James BD, Barnes LL, Mehta RI, Dams-O'Connor K et al (2022) Association of traumatic brain injury with and without loss of consciousness with neuropathologic outcomes in community-dwelling older persons. *JAMA Netw Open* 5:e229311. <https://doi.org/10.1001/jamanetworkopen.2022.9311>
- Agrawal S, Yu L, Nag S, Arfanakis K, Barnes LL, Bennett DA et al (2021) The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer's dementia in older persons. *Acta Neuropathol Commun* 9:156. <https://doi.org/10.1186/s40478-021-01260-0>
- Alafuzoff I, Pikkarainen M, Neumann M, Arzberger T, Al-Sarraj S, Bodi I et al (2015) Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. *J Neural Transm (Vienna)* 122:957–972. <https://doi.org/10.1007/s00702-014-1304-1>
- Amador-Ortiz C, Ahmed Z, Zehr C, Dickson DW (2007) Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. *Acta Neuropathol (Berl)* 113:245–252
- Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. *Ann Neurol* 61:435–445. <https://doi.org/10.1002/ana.21154>
- Aoki N, Murray ME, Ogaki K, Fujioka S, Rutherford NJ, Rademakers R et al (2015) Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLTDP type A. *Acta Neuropathol* 129:53–64. <https://doi.org/10.1007/s00401-014-1358-z>
- Arai T (2014) Significance and limitation of the pathological classification of TDP-43 proteinopathy. *Neuropathology* 34:578–588. <https://doi.org/10.1111/neup.12138>
- Arai T, Mackenzie IR, Hasegawa M, Nonaka T, Niizato K, Tsuchiya K et al (2009) Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. *Acta Neuropathol* 117:125–136. <https://doi.org/10.1007/s00401-008-0480-1>
- Arnold SJ, Dugger BN, Beach TG (2013) TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. *Acta Neuropathol* 126:51–57. <https://doi.org/10.1007/s00401-013-1110-0>
- Attems J, Toledo JB, Walker L, Gelpi E, Gentleman S, Halliday G et al (2021) Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. *Acta Neuropathol* 141:159–172. <https://doi.org/10.1007/s00401-020-02255-2>
- Ayaki T, Murata K, Kanazawa N, Uruha A, Ohmura K, Sugie K et al (2020) Myositis with sarcoplasmic inclusions in Nakajo-Nishimura syndrome: a genetic inflammatory myopathy. *Neuropathol Appl Neurobiol* 46:579–587. <https://doi.org/10.1111/nan.12614>
- Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D et al (2002) Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. *Alzheimer Dis Assoc Disord* 16:203–212

15. Blevins BL, Vinters HV, Love S, Wilcock DM, Grinberg LT, Schneider JA et al (2020) Brain arteriolosclerosis. *Acta Neuropathol.* <https://doi.org/10.1007/s00401-020-02235-6>
16. Boyle PA, Wang T, Yu L, Wilson RS, Dawe R, Arfanakis K et al (2021) To what degree is late life cognitive decline driven by age-related neuropathologies? *Brain.* <https://doi.org/10.1093/brain/awab092>
17. Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA et al (2019) Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. *Ann Neurol* 85:114–124. <https://doi.org/10.1002/ana.25380>
18. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. *Cell Tissue Res* 318:121–134. <https://doi.org/10.1007/s00441-004-0956-9>
19. Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. *J Neuropathol Exp Neurol* 70:960–969. <https://doi.org/10.1097/NEN.0b013e318232a379>
20. Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M et al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. *Ann Neurol* 74:20–38. <https://doi.org/10.1002/ana.23937>
21. Buciu M, Martin PR, Tosakulwong N, Murray ME, Petrucelli L, Senjem ML et al (2022) TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. *Neuroimage Clin* 34:102954. <https://doi.org/10.1016/j.nicl.2022.102954>
22. Buciu M, Whitwell JL, Baker MC, Rademakers R, Dickson DW, Josephs KA (2021) Old age genetically confirmed frontotemporal lobar degeneration with TDP-43 has limbic predominant TDP-43 deposition. *Neuropathol Appl Neurobiol.* <https://doi.org/10.1111/nan.12727>
23. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. *Acta Neuropathol* 114:5–22. <https://doi.org/10.1007/s00401-007-0237-2>
24. Carlos AF, Tosakulwong N, Weigand SD, Boeve BF, Knopman DS, Petersen RC et al (2022) Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. *Acta Neuropathol.* <https://doi.org/10.1007/s00401-022-02434-3>
25. Cho SH, Choi SM, Kim BC, Song WY, Kim HS, Lee KH (2020) An autopsy-proven case of limbic-predominant age-related TDP-43 encephalopathy. *Yonsei Med J* 61:731–735. <https://doi.org/10.3349/ymj.2020.61.8.731>
26. Chompoopong P, Milone M, Niu Z, Cui G, Mer G, Liewluck T (2022) A novel missense HNRNPA1 variant in the PY-NLS domain in a patient with late-onset distal myopathy. *Neuromuscul Disord* 32:521–526. <https://doi.org/10.1016/j.nmd.2022.03.009>
27. Chornenkyy Y, Fardo DW, Nelson PT (2019) Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. *Lab Invest* 99:993–1007. <https://doi.org/10.1038/s41374-019-0196-y>
28. Corey-Bloom J, Sabbagh MN, Bondi MW, Hansen L, Alford MF, Masliah E et al (1997) Hippocampal sclerosis contributes to dementia in the elderly. *Neurology* 48:154–160
29. Cykowski MD, Arumanayagam AS, Powell SZ, Rivera AL, Abner EL, Roman GC et al (2022) Patterns of amygdala region pathology in LATE-NC: subtypes that differ with regard to TDP-43 histopathology, genetic risk factors, and comorbid pathologies. *Acta Neuropathol.* <https://doi.org/10.1007/s00401-022-02416-5>
30. Davidson YS, Raby S, Foulds PG, Robinson A, Thompson JC, Sikkink S et al (2011) TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype. *Acta Neuropathol* 122:703–713. <https://doi.org/10.1007/s00401-011-0879-y>
31. Dickson DW, Davies P, Bevona C, Van Hoesven KH, Factor SM, Grober E et al (1994) Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans. *Acta Neuropathol* 88:212–221
32. Dickson DW, Josephs KA, Amador-Ortiz C (2007) TDP-43 in differential diagnosis of motor neuron disorders. *Acta Neuropathol* 114:71–79. <https://doi.org/10.1007/s00401-007-0234-5>
33. Dickson DW, Rademakers R, Nicholson AM, Schneider JA, Yu L, Bennett DA (2015) The TMEM106B locus and TDP-43 pathology in older persons without FTL. *Neurology* 85:1354–1355. <https://doi.org/10.1212/01.wnl.0000472918.79256.a9>
34. Dugan AJ, Nelson PT, Katsumata Y, Shade LMP, Boehme KL, Teylan MA et al (2021) Analysis of genes (TMEM106B, GRN, ABCG9, KCNMB2, and APOE) implicated in risk for LATE-NC and hippocampal sclerosis provides pathogenetic insights: a retrospective genetic association study. *Acta Neuropathol Commun* 9:152. <https://doi.org/10.1186/s40478-021-01250-2>
35. Fearon C, Koch M-L, Hefferman J, Heeney C, Lorigan J, Beausang A et al (2019) Phosphorylation-dependent TDP-43 antibodies: validation in a neurodegenerative brain bank cohort. *J Alzheimer's Parkinsonism Dement.* 3:1–4
36. Flanagan ME, Cholerton B, Latimer CS, Hemmy LS, Edland SD, Montine KS et al (2018) TDP-43 neuropathologic associations in the nun study and the honolulu-asia aging study. *J Alzheimers Dis* 66:1549–1558. <https://doi.org/10.3233/JAD-180162>
37. Forrest SL, Wagner S, Kim A, Kovacs GG (2022) Association of glial tau pathology and LATE-NC in the ageing brain. *Neurobiol Aging* 119:77–88. <https://doi.org/10.1016/j.neurobiolaging.2022.07.010>
38. Gauthreaux KM, Teylan MA, Katsumata Y, Mock C, Culhane JE, Chen YC et al (2022) Limbic-predominant age-related TDP-43 encephalopathy: medical and pathologic factors associated with comorbid hippocampal sclerosis. *Neurology* 98:e1422–e1433. <https://doi.org/10.1212/WNL.0000000000200001>
39. Geser F, Robinson JL, Malunda JA, Xie SX, Clark CM, Kwong LK et al (2010) Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. *Arch Neurol* 67:1238–1250. <https://doi.org/10.1001/archneurol.2010.254>
40. Goossens J, Vanmechelen E, Trojanowski JQ, Lee VM, Van Broeckhoven C, van der Zee J et al (2015) TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. *Acta Neuropathol Commun* 3:15. <https://doi.org/10.1186/s40478-015-0195-1>
41. Grothe MJ, Moscoso A, Silva-Rodriguez J, Lange C, Nho K, Saykin AJ et al (2022) Differential diagnosis of amnesic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC. *Alzheimers Dement.* <https://doi.org/10.1002/alz.12763>
42. Harrison WT, Lusk JB, Liu B, Ervin JF, Johnson KG, Green CL et al (2021) Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is independently associated with dementia and strongly associated with arteriolosclerosis in the oldest-old. *Acta Neuropathol.* <https://doi.org/10.1007/s00401-021-02360-w>
43. Hasegawa M, Arai T, Akiyama H, Nonaka T, Mori H, Hashimoto T et al (2007) TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. *Brain* 130:1386–1394. <https://doi.org/10.1093/brain/awm065>

44. Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y et al (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Ann Neurol* 64:60–70. <https://doi.org/10.1002/ana.21425>
45. Hatanpaa KJ, Raisanen JM, Herndon E, Burns DK, Foong C, Habib AA et al (2014) Hippocampal sclerosis in dementia, epilepsy, and ischemic injury: differential vulnerability of hippocampal subfields. *J Neuropathol Exp Neurol* 73:136–142. <https://doi.org/10.1097/OPX.0000000000000170>
46. Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K et al (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. *Brain Res* 1184:284–294. <https://doi.org/10.1016/j.brainres.2007.09.048>
47. Hokkanen SRK, Hunter S, Polvikoski TM, Keage HAD, Minett T, Matthews FE et al (2018) Hippocampal sclerosis, hippocampal neuron loss patterns and TDP-43 in the aged population. *Brain Pathol* 28:548–559. <https://doi.org/10.1111/bpa.12556>
48. Hokkanen SRK, Kero M, Kaivola K, Hunter S, Keage HAD, Kiviharju A et al (2020) Putative risk alleles for LATE-NC with hippocampal sclerosis in population-representative autopsy cohorts. *Brain Pathol* 30:364–372. <https://doi.org/10.1111/bpa.12773>
49. Hu WT, Josephs KA, Knopman DS, Boeve BF, Dickson DW, Petersen RC et al (2008) Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. *Acta Neuropathol* 116:215–220. <https://doi.org/10.1007/s00401-008-0400-4>
50. Huang W, Zhou Y, Tu L, Ba Z, Huang J, Huang N et al (2020) TDP-43: from Alzheimer's disease to limbic-predominant age-related TDP-43 encephalopathy. *Front Mol Neurosci* 13:26. <https://doi.org/10.3389/fnmol.2020.00026>
51. Hunter S, Hokkanen SRK, Keage HAD, Fleming J, Minett T, Polvikoski T et al (2020) TDP-43 related neuropathologies and phosphorylation state: associations with age and clinical Dementia in the Cambridge city over-75s cohort. *J Alzheimers Dis* 75:337–350. <https://doi.org/10.3233/JAD-191093>
52. Ichimata S, Yoshida K, Visanji NP, Lang AE, Nishida N, Kovacs GG (2022) Patterns of mixed pathologies in Down syndrome. *J Alzheimers Dis* 87:595–607. <https://doi.org/10.3233/JAD-215675>
53. Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M et al (2008) Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Am J Pathol* 173:182–194. <https://doi.org/10.2353/ajpath.2008.080003>
54. Ighodaro ET, Jicha GA, Schmitt FA, Neltner JH, Abner EL, Kryscio RJ et al (2015) Hippocampal sclerosis of aging can be segmental: two cases and review of the literature. *J Neuropathol Exp Neurol* 74:642–652. <https://doi.org/10.1097/NEN.0000000000000204>
55. Ighodaro ET, Nelson PT, Kukull WA, Schmitt FA, Abner EL, Caban-Holt A et al (2017) Challenges and considerations related to studying dementia in blacks/African Americans. *J Alzheimers Dis* 60:1–10. <https://doi.org/10.3233/JAD-170242>
56. Ihara R, Vincent BD, Baxter MR, Franklin EE, Hassenstab JJ, Xiong C et al (2018) Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. *Ann Neurol* 84:741–753. <https://doi.org/10.1002/ana.25344>
57. Jamerlan A, An SSA (2020) The influence of Abeta-dependent and independent pathways on TDP-43 proteinopathy in Alzheimer's disease: a possible connection to LATE-NC. *Neurobiol Aging* 95:161–167. <https://doi.org/10.1016/j.neurobiolaging.2020.06.020>
58. James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA (2016) TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. *Brain* 139:2983–2993. <https://doi.org/10.1093/brain/aww224>
59. Jellinger KA (1994) Hippocampal sclerosis: a common pathological feature of dementia in very old humans. *Acta Neuropathol* 88:599
60. Johnson VE, Stewart W, Trojanowski JQ, Smith DH (2011) Acute and chronically increased immunoreactivity to phosphorylation-independent but not pathological TDP-43 after a single traumatic brain injury in humans. *Acta Neuropathol* 122:715–726. <https://doi.org/10.1007/s00401-011-0909-9>
61. Josephs KA, Mackenzie I, Frosch MP, Bigio EH, Neumann M, Arai T et al (2019) LATE to the PART-y. *Brain* 142:e47. <https://doi.org/10.1093/brain/awz224>
62. Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Perkerson RB et al (2019) Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. *Acta Neuropathol* 137:227–238. <https://doi.org/10.1007/s00401-018-1951-7>
63. Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR et al (2014) Staging TDP-43 pathology in Alzheimer's disease. *Acta Neuropathol* 127:441–450. <https://doi.org/10.1007/s00401-013-1211-9>
64. Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L et al (2016) Updated TDP-43 in Alzheimer's disease staging scheme. *Acta Neuropathol* 131:571–585. <https://doi.org/10.1007/s00401-016-1537-1>
65. Josephs KA, Stroh A, Dugger B, Dickson DW (2009) Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. *Acta Neuropathol* 118:349–358. <https://doi.org/10.1007/s00401-009-0547-7>
66. Josephs KA, Whitwell JL, Knopman DS, Hu WT, Stroh DA, Baker M et al (2008) Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. *Neurology* 70:1850–1857
67. Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM et al (2015) TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. *Ann Neurol* 78:697–709. <https://doi.org/10.1002/ana.24493>
68. Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM et al (2014) TDP-43 is a key player in the clinical features associated with Alzheimer's disease. *Acta Neuropathol* 127:811–824. <https://doi.org/10.1007/s00401-014-1269-z>
69. Kadokura A, Yamazaki T, Kakuda S, Makioka K, Lemere CA, Fujita Y et al (2009) Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration. *Neurosci Lett* 463:87–92. <https://doi.org/10.1016/j.neulet.2009.06.024>
70. Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K (2009) Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. *Neuropathology* 29:566–573. <https://doi.org/10.1111/j.1440-1789.2009.01017.x>
71. Katsumata Y, Fardo DW, Kukull WA, Nelson PT (2018) Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer's disease and cerebrovascular disease pathologies. *Acta Neuropathol Commun* 6:142. <https://doi.org/10.1186/s40478-018-0641-y>
72. Keage HA, Hunter S, Matthews FE, Ince PG, Hodges J, Hokkanen SR et al (2014) TDP-43 pathology in the population: prevalence and associations with dementia and age. *J Alzheimers Dis* 42:641–650. <https://doi.org/10.3233/JAD-132351>

73. Kero M, Raunio A, Polvikoski T, Tienari PJ, Paetau A, Myllykangas L (2018) Hippocampal sclerosis in the oldest old: a Finnish population-based study. *J Alzheimers Dis* 63:263–272. <https://doi.org/10.3233/JAD-171068>
74. Klein HU, Trumpff C, Yang HS, Lee AJ, Picard M, Bennett DA et al (2021) Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer's disease brain. *Mol Neurodegener* 16:75. <https://doi.org/10.1186/s13024-021-00495-8>
75. Kokubo Y, Morimoto S, Sasaki R, Hasegawa M, Ishiura H, Tsuji S et al (2022) An immigrant family with Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex. *Neurol Sci* 43:1423–1425. <https://doi.org/10.1007/s10072-021-05737-7>
76. Koper MJ, Tome SO, Gawor K, Belet A, Van Schoor E, Schaevebeke J et al (2022) LATE-NC aggravates GVD-mediated necroptosis in Alzheimer's disease. *Acta Neuropathol Commun* 10:128. <https://doi.org/10.1186/s40478-022-01432-6>
77. Koper MJ, Van Schoor E, Ospitalieri S, Vandenberghe R, Vandebulcke M, von Arnim CAF et al (2020) Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer's disease. *Acta Neuropathol* 139:463–484. <https://doi.org/10.1007/s00401-019-02103-y>
78. Koyano S, Yagishita S, Tada M, Doi H, Uchihara T, Tanaka F (2022) Parallel appearance of polyglutamine and transactivation-responsive DNA-binding protein 43 and their complementary subcellular localization in brains of patients with spinocerebellar ataxia type 2. *J Neuropathol Exp Neurol* 81:535–544. <https://doi.org/10.1093/jnen/nlac032>
79. Kwong LK, Irwin DJ, Walker AK, Xu Y, Riddle DM, Trojanowski JQ et al (2014) Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins. *Acta Neuropathol Commun* 2:33. <https://doi.org/10.1186/2051-5960-2-33>
80. Lachner C, Day GS, Camsari GB, Kouri N, Ertekin-Taner N, Boeve BF et al (2022) Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old. *J Alzheimers Dis* 90(1):405–417. <https://doi.org/10.3233/JAD-220440>
81. Latimer CS, Burke BT, Liachko NF, Currey HN, Kilgore MD, Gibbons LE et al (2019) Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. *Acta Neuropathol Commun* 7:91. <https://doi.org/10.1186/s40478-019-0743-1>
82. Lee EB (2018) Integrated neurodegenerative disease autopsy diagnosis. *Acta Neuropathol* 135:643–646. <https://doi.org/10.1007/s00401-018-1827-x>
83. Lee EB, Lee VM, Trojanowski JQ, Neumann M (2008) TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. *Acta Neuropathol* 115:305–311. <https://doi.org/10.1007/s00401-007-0331-5>
84. Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK et al (2017) Expansion of the classification of FTLTDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. *Acta Neuropathol* 134:65–78. <https://doi.org/10.1007/s00401-017-1679-9>
85. Leverenz JB, Agustin CM, Tsuang D, Peskind ER, Edland SD, Nochlin D et al (2002) Clinical and neuropathological characteristics of hippocampal sclerosis: a community-based study. *Arch Neurol* 59:1099–1106
86. Leverenz JB, Lipton AM (2008) Clinical aspects of hippocampal sclerosis. *Handb Clin Neurol* 89:565–567
87. Lin WL, Castanedes-Casey M, Dickson DW (2009) Transactivation response DNA-binding protein 43 microvasculopathy in frontotemporal degeneration and familial Lewy body disease. *J Neuropathol Exp Neurol* 68:1167–1176. <https://doi.org/10.1097/NEN.0b013e3181baacec>
88. Lopez OL, Kofler J, Chang Y, Berman SB, Becker JT, Sweet RA et al (2020) Hippocampal sclerosis, TDP-43, and the duration of the symptoms of dementia of AD patients. *Ann Clin Transl Neurol* 7:1546–1556. <https://doi.org/10.1002/acn3.51135>
89. Mackenzie IR, Frick P, Neumann M (2014) The neuropathology associated with repeat expansions in the C9ORF72 gene. *Acta Neuropathol* 127:347–357. <https://doi.org/10.1007/s00401-013-1232-4>
90. Mackenzie IR, Neumann M (2017) Reappraisal of TDP-43 pathology in FTLTDP subtypes. *Acta Neuropathol* 134:79–96. <https://doi.org/10.1007/s00401-017-1716-8>
91. Mackenzie IR, Neumann M (2020) Subcortical TDP-43 pathology patterns validate cortical FTLTDP subtypes and demonstrate unique aspects of C9orf72 mutation cases. *Acta Neuropathol* 139:83–98. <https://doi.org/10.1007/s00401-019-02070-4>
92. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E et al (2011) A harmonized classification system for FTLTDP pathology. *Acta Neuropathol* 122:111–113. <https://doi.org/10.1007/s00401-011-0845-8>
93. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. *Acta Neuropathol* 119:1–4. <https://doi.org/10.1007/s00401-009-0612-2>
94. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J et al (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. *Acta Neuropathol* 117:15–18. <https://doi.org/10.1007/s00401-008-0460-5>
95. McAleese KE, Walker L, Erskine D, Johnson M, Koss D, Thomas AJ et al (2020) Concomitant LATE-NC in Alzheimer's disease is not associated with increased tau or amyloid-beta pathological burden. *Neuropathol Appl Neurobiol* 46:722–734. <https://doi.org/10.1111/nan.12664>
96. McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CD, Litvan I et al (2016) The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. *Acta Neuropathol* 131:75–86. <https://doi.org/10.1007/s00401-015-1515-z>
97. McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW et al (2010) TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. *J Neuropathol Exp Neurol* 69:918–929. <https://doi.org/10.1097/NEN.0b013e3181ee7d85>
98. Melikyan ZA, Corrada MM, Leiby AM, Sajjadi SA, Bukhari S, Montine TJ et al (2022) Cognitive resilience to three dementia-related neuropathologies in an oldest-old man: a case report from the 90+ study. *Neurobiol Aging* 116:12–15. <https://doi.org/10.1016/j.neurobiolaging.2022.03.009>
99. Mol MO, van Rooij JGJ, Wong TH, Melhem S, Verkerk A, Kievit AJA et al (2021) Underlying genetic variation in familial frontotemporal dementia: sequencing of 198 patients. *Neurobiol Aging* 97:148e149–148e116. <https://doi.org/10.1016/j.neurobiolaging.2020.07.014>
100. Montine TJ, Corrada MM, Kawas C, Bukhari S, White L, Tian L et al (2022) Association of cognition and dementia with neuropathologic changes of Alzheimer disease and other conditions in the oldest-old. *Neurology*. <https://doi.org/10.1212/WNL.0000000000200832>
101. Murakami A, Koga S, Sekiya H, Oskarsson B, Boylan K, Petrucci L et al (2022) Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology. *Brain Pathol*. <https://doi.org/10.1111/bpa.13100>
102. Murray ME, Bieniek KF, Banks Greenberg M, DeJesus-Hernandez M, Rutherford NJ, van Blitterswijk M et al (2013) Progressive amnesic dementia, hippocampal sclerosis, and

- mutation in C9ORF72. *Acta Neuropathol* 126:545–554. <https://doi.org/10.1007/s00401-013-1161-2>
103. Murray ME, Cannon A, Graff-Radford NR, Liesinger AM, Rutherford NJ, Ross OA et al (2014) Differential clinicopathologic and genetic features of late-onset amnesic dementias. *Acta Neuropathol* 128:411–421. <https://doi.org/10.1007/s00401-014-1302-2>
 104. Nag S, Barnes LL, Yu L, Wilson RS, Bennett DA, Schneider JA (2020) Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents. *Neurology* 95:e2056–e2064. <https://doi.org/10.1212/WNL.0000000000010602>
 105. Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA (2018) TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease. *Acta Neuropathol Commun* 6:33. <https://doi.org/10.1186/s40478-018-0531-3>
 106. Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA et al (2015) Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. *Ann Neurol* 77:942–952. <https://doi.org/10.1002/ana.24388>
 107. Nag S, Yu L, Wilson RS, Chen EY, Bennett DA, Schneider JA (2017) TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLN. *Neurology* 88:653–660. <https://doi.org/10.1212/WNL.0000000000003610>
 108. Nascimento C, Di Lorenzo Alho AT, Bazan Conceicao Amaral C, Leite REP, Nitrini R, Jacob-Filho W et al (2018) Prevalence of transactive response DNA-binding protein 43 (TDP-43) proteinopathy in cognitively normal older adults: systematic review and meta-analysis. *Neuropathol Appl Neurobiol* 44:286–297. <https://doi.org/10.1111/nan.12430>
 109. Nascimento C, Suemoto CK, Rodriguez RD, Alho AT, Leite RP, Farfel JM et al (2016) Higher prevalence of TDP-43 proteinopathy in cognitively normal asians: a clinicopathological study on a multiethnic sample. *Brain Pathol* 26:177–185. <https://doi.org/10.1111/bpa.12296>
 110. Nelson PT, Abner EL, Patel E, Anderson S, Wilcock DM, Kryscio RJ et al (2018) The amygdala as a locus of pathologic misfolding in neurodegenerative diseases. *J Neuropathol Exp Neurol* 77:2–20. <https://doi.org/10.1093/jnen/nlx099>
 111. Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD et al (2010) Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. *Brain Pathol* 20:66–79. <https://doi.org/10.1111/j.1750-3639.2008.00244.x>
 112. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J Neuropathol Exp Neurol* 71:362–381. <https://doi.org/10.1097/NEN.0b013e31825018f7>
 113. Nelson PT, Brayne C, Flanagan ME, Abner EL, Agrawal S, Attems J et al (2022) Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. *Acta Neuropathol*. <https://doi.org/10.1007/s00401-022-02444-1>
 114. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K et al (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. *Brain*. <https://doi.org/10.1093/brain/awz099>
 115. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K et al (2019) Reply: LATE to the PART-y. *Brain* 142:e48. <https://doi.org/10.1093/brain/awz226>
 116. Nelson PT, Gal Z, Wang WX, Niedowicz DM, Artiushin SC, Wycoff S et al (2019) TDP-43 proteinopathy in aging: Associations with risk-associated gene variants and with brain parenchymal thyroid hormone levels. *Neurobiol Dis* 125:67–76. <https://doi.org/10.1016/j.nbd.2019.01.013>
 117. Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E et al (2011) Hippocampal sclerosis in advanced age: clinical and pathological features. *Brain* 134:1506–1518. <https://doi.org/10.1093/brain/awr053>
 118. Nelson PT, Smith CD, Abner EL, Wilfred BJ, Wang WX, Neltner JH et al (2013) Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. *Acta Neuropathol* 126:161–177. <https://doi.org/10.1007/s00401-013-1154-1>
 119. Neumann M, Frick P, Paron F, Kosten J, Buratti E, Mackenzie IR (2020) Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLN-TDP subtypes. *Acta Neuropathol* 140:645–658. <https://doi.org/10.1007/s00401-020-02207-w>
 120. Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y et al (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. *Acta Neuropathol* 117:137–149. <https://doi.org/10.1007/s00401-008-0477-9>
 121. Neumann M, Lee EB, Mackenzie IR (2021) Frontotemporal lobar degeneration TDP-43-immunoreactive pathological subtypes: clinical and mechanistic significance. *Adv Exp Med Biol* 1281:201–217. https://doi.org/10.1007/978-3-030-51140-1_13
 122. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 314:130–133
 123. Nguyen ML, Huie EZ, Whitmer RA, George KM, Dugger BN (2022) Neuropathology studies of dementia in US persons other than non-hispanic whites. *Free Neuropathol*. <https://doi.org/10.17879/freeneuropathology-2022-3795>
 124. Nishihira Y, Gefen T, Mao Q, Appin C, Kohler M, Walker J et al (2019) Revisiting the utility of TDP-43 immunoreactive (TDP-43-ir) pathology to classify FTLN-TDP subtypes. *Acta Neuropathol* 138:167–169. <https://doi.org/10.1007/s00401-019-02024-w>
 125. Pao WC, Dickson DW, Crook JE, Finch NA, Rademakers R, Graff-Radford NR (2011) Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. *Alzheimer Dis Assoc Disord* 25:364–368. <https://doi.org/10.1097/WAD.0b013e31820f8f50>
 126. Postupna N, Rose SE, Gibbons LE, Coleman NM, Hellstern LL, Ritchie K et al (2021) The delayed neuropathological consequences of traumatic brain injury in a community-based sample. *Front Neurol* 12:624696. <https://doi.org/10.3389/fneur.2021.624696>
 127. Power MC, Mormino E, Soldan A, James BD, Yu L, Armstrong NM et al (2018) Combined neuropathological pathways account for age-related risk of dementia. *Ann Neurol* 84:10–22. <https://doi.org/10.1002/ana.25246>
 128. Prater KE, Latimer CS, Jayadev S (2022) Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes. *Glia* 70:239–255. <https://doi.org/10.1002/glia.24096>
 129. Riku Y, Iwasaki Y, Ishigaki S, Akagi A, Hasegawa M, Nishioka K et al (2022) Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. *Brain*. <https://doi.org/10.1093/brain/awac091>
 130. Robinson JL, Corrada MM, Kovacs GG, Dominique M, Caswell C, Xie SX et al (2018) Non-Alzheimer's contributions to dementia and cognitive resilience in the 90+ study. *Acta Neuropathol*. <https://doi.org/10.1007/s00401-018-1872-5>
 131. Robinson JL, Porta S, Garrett FG, Zhang P, Xie SX, Suh E et al (2020) Limbic-predominant age-related TDP-43 encephalopathy

- differs from frontotemporal lobar degeneration. *Brain* 143:2844–2857. <https://doi.org/10.1093/brain/awaa219>
132. Robinson JL, Richardson H, Xie SX, Suh E, Van Deerlin VM, Alfaró B et al (2021) The development and convergence of co-pathologies in Alzheimer's disease. *Brain* 144:953–962. <https://doi.org/10.1093/brain/awaa438>
 133. Sakuwa M, Adachi T, Suzuki Y, Yoshida K, Fukuda H, Miura H et al (2021) First Japanese autopsy case showing LRRK2 mutation G2019S and TDP-43 proteinopathy. *Parkinsonism Relat Disord* 91:85–87. <https://doi.org/10.1016/j.parkreldis.2021.09.009>
 134. Saveri P, Magri S, Maderna E, Balistreri F, Lombardi R, Ciano C et al (2022) DNAJB2-related Charcot-Marie-Tooth disease type 2: pathomechanism insights and phenotypic spectrum widening. *Eur J Neurol* 29:2056–2065. <https://doi.org/10.1111/ene.15326>
 135. Smirnov DS, Salmon DP, Galasko D, Edland SD, Pizzo DP, Goodwill V et al (2022) TDP-43 pathology exacerbates cognitive decline in primary age-related tauopathy. *Ann Neurol*. <https://doi.org/10.1002/ana.26438>
 136. Sommer W (1880) Erkrankung des Ammon's horn als aetiologie ches moment der epilepsien. *Arch Psychiatr Nurs* 10:631–675
 137. Tan RH, Kril JJ, Fatima M, McGeachie A, McCann H, Shepherd C et al (2015) TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. *Brain* 138:3110–3122. <https://doi.org/10.1093/brain/awv220>
 138. Tazwar M, Evia AM, Tamhane AA, Ridwan AR, Leurgans SE, Bennett DA et al (2022) Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is associated with lower R2 relaxation rate: an ex-vivo MRI and pathology investigation. *Neurobiol Aging* 117:128–138. <https://doi.org/10.1016/j.neurobiolaging.2022.05.009>
 139. Thal DR, Del Tredici K, Ludolph AC, Hoozemans JJ, Rozemuller AJ, Braak H et al (2011) Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. *Acta Neuropathol* 122:577–589. <https://doi.org/10.1007/s00401-011-0871-6>
 140. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. *Neurology* 58:1791–1800
 141. Thal DR, von Arnim C, Griffin WS, Yamaguchi H, Mrak RE, Attems J et al (2013) Pathology of clinical and preclinical Alzheimer's disease. *Eur Arch Psychiatry Clin Neurosci* 263(Suppl 2):S137–145. <https://doi.org/10.1007/s00406-013-0449-5>
 142. Thom M (2009) Hippocampal sclerosis: progress since Sommer. *Brain Pathol* 19:565–572. <https://doi.org/10.1111/j.1750-3639.2008.00201.x>
 143. Tome SO, Vandenberghe R, Ospitalieri S, Van Schoor E, Tousseyn T, Otto M et al (2020) Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: relationship with clinical phenotypes. *Acta Neuropathol Commun* 8:61. <https://doi.org/10.1186/s40478-020-00934-5>
 144. Trieu T, Sajjadi SA, Kawas CH, Nelson PT, Corrada MM (2018) Risk factors of hippocampal sclerosis in the oldest old: the 90+ study. *Neurology* 91:e1788–e1798. <https://doi.org/10.1212/WNL.0000000000006455>
 145. Troncoso JC, Kawas CH, Chang CK, Folstein MF, Hedreen JC (1996) Lack of association of the apoE4 allele with hippocampal sclerosis dementia. *Neurosci Lett* 204:138–140
 146. Uchino A, Takao M, Hatsuta H, Sumikura H, Nakano Y, Nogami A et al (2015) Incidence and extent of TDP-43 accumulation in aging human brain. *Acta Neuropathol Commun* 3:35. <https://doi.org/10.1186/s40478-015-0215-1>
 147. Uemura MT, Robinson JL, Cousins KAQ, Tropea TF, Kargilis DC, McBride JD et al (2021) Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. *Acta Neuropathol*. <https://doi.org/10.1007/s00401-021-02383-3>
 148. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. *J Neuropathol Exp Neurol* 67:555–564. <https://doi.org/10.1097/NEN.0b013e31817713b5>
 149. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M et al (2008) Concomitant TAR-DNA-binding in Alzheimer disease and protein 43 pathology is present corticobasal degeneration but not in other tauopathies. *J Neuropathol Exp Neurol* 67:555–564. <https://doi.org/10.1097/NEN.0b013e31817713b5>
 150. Van Mossevelde S, Engelborghs S, van der Zee J, Van Broeckhoven C (2018) Genotype-phenotype links in frontotemporal lobar degeneration. *Nat Rev Neurol* 14:363–378. <https://doi.org/10.1038/s41582-018-0009-8>
 151. Van Schoor E, Koper MJ, Ospitalieri S, Dedeene L, Tome SO, Vandenberghe R et al (2021) Necrosome-positive granulovacuolar degeneration is associated with TDP-43 pathological lesions in the hippocampus of ALS/FTLD cases. *Neuropathol Appl Neurobiol* 47:328–345. <https://doi.org/10.1111/nan.12668>
 152. Walker AK, Daniels CM, Goldman JE, Trojanowski JQ, Lee VM, Messing A (2014) Astrocytic TDP-43 pathology in Alexander disease. *J Neurosci* 34:6448–6458. <https://doi.org/10.1523/JNEUROSCI.0248-14.2014>
 153. Wang SJ, Guo Y, Ervin JF, Lusk JB, Luo S (2022) Neuropathological associations of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) differ between the oldest-old and younger-old. *Acta Neuropathol* 144:45–57. <https://doi.org/10.1007/s00401-022-02432-5>
 154. Wegiel J, Flory M, Kuchna I, Nowicki K, Wegiel J, Ma SY et al (2022) Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome. *Acta Neuropathol Commun* 10:2. <https://doi.org/10.1186/s40478-021-01300-9>
 155. White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW et al (2002) Cerebrovascular pathology and dementia in autopsied Honolulu-Asia aging study participants. *Ann NY Acad Sci* 977:9–23
 156. Wider C, Dickson DW, Stoessl AJ, Tsuboi Y, Chapon F, Gutmann L et al (2009) Pallidonigral TDP-43 pathology in perry syndrome. *Parkinsonism Relat Disord* 15:281–286. <https://doi.org/10.1016/j.parkreldis.2008.07.005>
 157. Yamashita R, Beck G, Yonenobu Y, Inoue K, Mitsutake A, Ishiura H et al (2022) TDP-43 proteinopathy presenting with typical symptoms of Parkinson's disease. *Mov Disord*. <https://doi.org/10.1002/mds.29048>
 158. Zabar Y, Carson KA, Troncoso JC, Kawas CH (1998) Dementia due to hippocampal sclerosis: clinical features and comparison to Alzheimer's disease. *Neurology* 50(4):A59–A60
 159. Zarow C, Sitzer TE, Chui HC (2008) Understanding hippocampal sclerosis in the elderly: epidemiology, characterization, and diagnostic issues. *Curr Neurol Neurosci Rep* 8:363–370
 160. Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L et al (2005) Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. *Ann Neurol* 57:896–903. <https://doi.org/10.1002/ana.20503>

161. Zarow C, Weiner MW, Ellis WG, Chui HC (2012) Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample. *Brain Behav* 2:435–442. <https://doi.org/10.1002/brb3.66>
162. Zhang X, Sun B, Wang X, Lu H, Shao F, Rozemuller AJM et al (2018) Phosphorylated TDP-43 staging of primary age-related tauopathy. *Neurosci Bull.* <https://doi.org/10.1007/s12264-018-0300-0>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Peter T. Nelson¹ · Edward B. Lee² · Matthew D. Cykowski³ · Irina Alafuzoff⁴ · Konstantinos Arfanakis^{5,6} · Johannes Attems⁷ · Carol Brayne⁸ · Maria M. Corrada⁹ · Brittany N. Dugger¹⁰ · Margaret E. Flanagan¹¹ · Bernardino Ghetti¹² · Lea T. Grinberg¹³ · Murray Grossman² · Michel J. Grothe¹⁴ · Glenda M. Halliday¹⁵ · Masato Hasegawa¹⁶ · Suvi R. K. Hokkanen⁸ · Sally Hunter⁸ · Kurt Jellinger¹⁷ · Claudia H. Kawas⁹ · C. Dirk Keene¹⁸ · Naomi Kouri¹⁹ · Gabor G. Kovacs^{20,21,22,23} · James B. Leverenz²⁴ · Caitlin S. Latimer¹⁸ · Ian R. Mackenzie²⁵ · Qinwen Mao²⁶ · Kirsty E. McAleese⁷ · Richard Merrick⁸ · Thomas J. Montine²⁷ · Melissa E. Murray¹⁹ · Liisa Myllykangas²⁸ · Sukriti Nag⁵ · Janna H. Neltner¹ · Kathy L. Newell¹² · Robert A. Rissman²⁹ · Yuko Saito³⁰ · S. Ahmad Sajjadi⁹ · Katherine E. Schwetye³¹ · Andrew F. Teich³² · Dietmar R. Thal^{33,34} · Sandra O. Tomé³³ · Juan C. Troncoso³⁵ · Shih-Hsiu J. Wang³⁶ · Charles L. White III³⁷ · Thomas Wisniewski³⁸ · Hyun-Sik Yang³⁹ · Julie A. Schneider⁵ · Dennis W. Dickson¹⁹ · Manuela Neumann⁴⁰

¹ University of Kentucky, Rm 575 Todd Building, Lexington, KY, USA

² University of Pennsylvania, Philadelphia, PA, USA

³ Houston Methodist Hospital, Houston, TX, USA

⁴ Uppsala University, Uppsala, Sweden

⁵ Rush University Medical Center, Chicago, IL, USA

⁶ Illinois Institute of Technology, Chicago, IL, USA

⁷ Newcastle University, Newcastle Upon Tyne, UK

⁸ University of Cambridge, Cambridge, UK

⁹ University of California, Irvine, CA, USA

¹⁰ University of California, Davis, CA, USA

¹¹ Northwestern University Medical Center, Chicago, IL, USA

¹² Indiana University, Indianapolis, IN, USA

¹³ University of California, San Francisco, CA, USA

¹⁴ Unidad de Trastornos del Movimiento, Servicio de Neurología Y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain

¹⁵ University of Sydney, Sydney, NSW, Australia

¹⁶ Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

¹⁷ Institute of Clinical Neurobiology, Vienna, Austria

¹⁸ University of Washington, Seattle, WA, USA

¹⁹ Mayo Clinic, Jacksonville, FL, USA

²⁰ Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Canada

²¹ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada

²² Laboratory Medicine Program, University Health Network, Toronto, Canada

²³ Institute of Neurology, Medical University of Vienna, Vienna, Austria

²⁴ The Cleveland Clinic, Cleveland, OH, USA

²⁵ The University of British Columbia, Vancouver, BC, Canada

²⁶ University of Utah, Salt Lake City, UT, USA

²⁷ Stanford University, Stanford, CA, USA

²⁸ University of Helsinki and Helsinki University Hospital, Helsinki, Finland

²⁹ University of California San Diego, San Diego, CA, USA

³⁰ Tokyo Metropolitan Geriatric Hospital & Institute of Gerontology, Tokyo, Japan

³¹ Washington University, St. Louis, MO, USA

³² Columbia University, New York, NY, USA

³³ Laboratory for Neuropathology, Department of Imaging and Pathology, and Leuven Brain Institute, KU Leuven, Leuven, Belgium

³⁴ Department of Pathology, University Hospital Leuven, Leuven, Belgium

³⁵ Johns Hopkins University, Baltimore, MD, USA

³⁶ Duke University, Durham, NC, USA

³⁷ University of Texas Southwestern Medical Center, Dallas, TX, USA

³⁸ New York University Grossman School of Medicine, New York, NY, USA

³⁹ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

⁴⁰ University of Tübingen and DZNE Tübingen, Tübingen, Germany